News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stemline Therapeutics, Inc. (STML) Announces Closing of $60 Million Public Offering of Common Stock



5/22/2013 9:44:58 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, May 22, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced the closing of its previously announced underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $14.50 per share. The gross proceeds to Stemline from the public offering are $60 million, before underwriting discounts and commissions and other offering expenses payable by Stemline.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES